sprite-preloader
Anzeige
Mehr »
Samstag, 21.10.2017 Börsentäglich über 12.000 News von 567 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Passende Knock-Outs zu Ihrer Suchanfrage (Anzeige)
Erweiterte
Suche
lynx
Ad hoc-Mitteilungen

WKN: A1180P ISIN: US67576A1007 Ticker-Symbol: 0OT 
Aktie:
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
OCULAR THERAPEUTIX INC Chart 1 Jahr
1-Woche-Intraday-Chart
OCULAR THERAPEUTIX INC 1-Woche-Intraday-Chart
RealtimeGeldBriefZeit
4,682
4,752
20.10.
11.08.2017 | 15:57
(5 Leser)
Schrift ändern:
(0 Bewertungen)

ACCESSWIRE·Mehr Nachrichten von ACCESSWIRE

NEW YORK, NY / ACCESSWIRE / August 11, 2017 / The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Ocular Therapeutix, Inc. ("Ocular Therapeutix") (NASDAQ: OCUL) securities between March 10, 2016 and July 11, 2017.

Click here to learn about the case: http://www.wongesq.com/pslra-sb/ocular-therapeutix-inc?wire=1. There is no cost or obligation to you.

According to the complaint, throughout the Class Period, the Company issued materially false and misleading statements and/or failed to disclose that: (i) Ocular failed to adequately address issues identified in the First Form 483; (ii) Ocular's re-submitted NDA would not be approved by the July 19, 2017 PDUFA date because the Company could not timely and adequately address the FDA-identified manufacturing and control issues; (iii) Ocular's continued manufacturing issues imperil the approval of DEXTENZA; and (v) as a result, Defendants' public statements were materially false and misleading at all relevant times.

If you suffered a loss in Ocular Therapeutix, you have until September 5, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email vw@wongesq.com, by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-sb/ocular-therapeutix-inc?wire=1.

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

SOURCE: The Law Offices of Vincent Wong


© 2017 ACCESSWIRE